Cartridge-Based Thromboelastography Can Be Used to Monitor and Quantify the Activity of Unfractionated and Low-Molecular-Weight Heparins

Abstract

Thromboelastography is increasingly utilized in the management of bleeding and thrombotic complications where heparin management remains a cornerstone. This study assessed the feasibility of the cartridge-based TEG^® 6s system (Haemonetics Corp., Braintree, Massachusetts, United States) to monitor and quantify the effect of unfractionated and low-molecular-weight heparin (UFH and LMWH). Blood samples from healthy donors were spiked with UFH (n = 23; 0–1.0 IU/mL) or LMWH (enoxaparin; n = 22; 0–1.5 IU/mL). Functional fibrinogen maximum amplitude (CFF.MA), RapidTEG activated clotting time (CRT.ACT), and kaolin and kaolin with heparinase reaction time (CK.R and CKH.R) were evaluated for their correlation with heparin concentrations, as well as the combination parameters ΔCK.R − CKH.R, ratio CK.R/CKH.R, and ratio CKH.R/CK.R. Nonlinear mixed-effect modelling was used to study the relationship between concentrations and parameters, and Bayesian classification modelling for the prediction of therapeutic ranges. CK.R and CRT.ACT strongly correlated with the activity of LMWH and UFH (p < 0.001). Using combination parameters, heparin activity could be accurately quantified in the range of 0.05 to 0.8 IU/mL for UFH and 0.1 to 1.5 IU/mL for LMWH. CRT.ACT was able to quantify heparin activity at higher concentrations but was only different from the reference range (p < 0.05) at >0.5 IU/mL for UFH and >1.5 IU/mL for LMWH. Combination parameters classified blood samples into subtherapeutic, therapeutic, and supratherapeutic heparin ranges, with an accuracy of >90% for UFH, and >78% for LMWH. This study suggests that TEG 6s can effectively monitor and quantify heparin activity for LMWH and UFH. Additionally, combination parameters can be used to classify blood samples into therapeutic ranges based on heparin activity.

Keywords

thromboelastography - point-of-care diagnostic system - low-molecular-weight heparin - heparin

^* These authors contributed equally.

• References

• 1 Hoffman M. Heparins: clinical use and laboratory monitoring. Lab Med 2010; 41 (10) 621-626
• 2 Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med 2015; 16 (01) 11-17
• 3 O'Carroll-Kuehn BU, Meeran H. Management of coagulation during cardiopulmonary bypass. Contin Educ Anaesth Crit Care Pain 2007; 7 (06) 195-198
• 4 Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. Pharmaceuticals (Basel) 2016; 9 (03) E38
• 5 Egan G, Ensom MHH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm 2015; 68 (01) 33-47
• 6 Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS One 2015; 10 (01) e0116835
• 7 Lehman CM, Frank EL. Laboratory monitoring of heparin therapy: partial thromboplastin time or anti-Xa assay?. Lab Med 2009; 40 (01) 47-51
• 8 Whitman-Purves E, Coons JC, Miller T. , et al. Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. Clin Appl Thromb Hemost 2018; 24 (02) 310-316
• 9 Bürki S, Brand B, Escher R, Wuillemin WA, Nagler M. Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions. BMJ Open 2018; 8 (06) e022943
• 10 Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin?. Thromb Res 2017; 157: 157-161
• 11 Vera-Aguilera J, Yousef H, Beltran-Melgarejo D. , et al. Clinical scenarios for discordant anti-Xa. Adv Hematol 2016; 2016: 4054806
• 12 Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 165-186
• 13 National Institute for Clinical Excellence. Detecting, managing and monitoring haemostasis: viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems). 2014 . Available at: https://www.nice.org.uk/guidance/dg13 . Accessed July 2018
• 14 Deppe AC, Weber C, Zimmermann J. , et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 2016; 203 (02) 424-433
• 15 Dias JD, Haney EI, Mathew BA, Lopez-Espina CG, Orr AW, Popovsky MA. New-generation thromboelastography: comprehensive evaluation of citrated and heparinized blood sample storage effect on clot-forming variables. Arch Pathol Lab Med 2017; 141 (04) 569-577
• 16 Hartmann J, Mason D, Achneck H. Thromboelastography (TEG) point-of-care diagnostic for hemostasis management. Point Care 2018; 17 (01) 15-22
• 17 Ramiz S, Hartmann J, Young G, Escobar MA, Chitlur M. Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia. Am J Hematol 2019; 94 (02) 249-256
• 18 Tekkesin N, Tekkesin M, Kaso G. Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery. Anatol J Cardiol 2015; 15 (11) 932-937
• 19 Coppell JA, Thalheimer U, Zambruni A. , et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis 2006; 17 (02) 97-104
• 20 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88 (02) 312-319
• 21 Food and Drug Administration (FDA). TEG®6s system indications for use. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160502.pdf . Accessed April 2018
• 22 Gurbel PA, Bliden KP, Tantry US. , et al. First report of the point-of-care TEG: a technical validation study of the TEG-6S system. Platelets 2016; 27 (07) 642-649
• 23 Haemonetics. TEG®6S haemostasis analyser system brochure (US). 2015 . Available at: https://www.haemonetics.com/~/media/Sharepoint/Devices/TEG/Marketing/Brochures/TEG6s_Brochure/COL-COPY-000918-US_Brochure_TEG6s.pdf.pdf . Accessed April 2018
• 24 Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol 2000; 113 (05) 725-731
• 25 Ranucci M, Baryshnikova E, Cotza M. , et al; Group for the Surgical and Clinical Outcome Research (SCORE). Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both?. Minerva Anestesiol 2016; 82 (08) 858-866
• 26 Lequier LAG, Al-Ibrahim O, Bembea M, Brodie DBT. ELSO anticoagulation guideline. 2014 . Available at: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8-2014-table-contents.pdf . Accessed June 2018
• 27 Artang R, Frandsen NJ, Nielsen JD. Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study. Thromb J 2009; 7: 14
• 28 White H, Sosnowski K, Bird R, Jones M, Solano C. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit. Blood Coagul Fibrinolysis 2012; 23 (04) 304-310
• 29 Panigada M, , E Iapichino G, Brioni M. , et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care 2018; 8 (01) 7
• 30 Horowitz GL, Altaie S, Boyd JC. , et al. Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Vol. 28. Wayne, PA: Clinical and Laboratory Standards Institute; 2010
• 31 Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010; 30 (04) 253-257
• 32 Ramos-Esquivel A, Salazar-Sánchez L. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin. Thromb Res 2013; 132 (04) 433-436
• 33 Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22 (02) 137-142
• 34 Byun JH, Jang IS, Kim JW, Koh EH. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Blood Res 2016; 51 (03) 171-174
• 35 da Luz LT, Nascimento B, Rizoli S. Thrombelastography (TEG®): practical considerations on its clinical use in trauma resuscitation. Scand J Trauma Resusc Emerg Med 2013; 21: 29
• 36 Doran CM, Woolley T, Midwinter MJ. Feasibility of using rotational thromboelastometry to assess coagulation status of combat casualties in a deployed setting. J Trauma 2010; 69 (Suppl. 01) S40-S48
• 37 Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S. Point-of-care testing in haemostasis. Br J Haematol 2010; 150 (05) 501-514
• 38 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (02) 228-232
• 39 Klein SM, Slaughter TF, Vail PT. , et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg 2000; 91 (05) 1091-1095
• 40 Alexander DC, Butt WW, Best JD, Donath SM, Monagle PT, Shekerdemian LS. Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. Thromb Res 2010; 125 (05) 387-392
• 41 Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma 2009; 66 (06) 1509-1515 , discussion 1515–1517